Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Antonia Potarca"'
1
Akademický článek
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Autor: Peter A. Merkel, John Niles, Richard Jimenez, Robert F. Spiera, Brad H. Rovin, Andrew Bomback, Christian Pagnoux, Antonia Potarca, Thomas J. Schall, Pirow Bekker, for the CLASSIC Investigators
Publikováno v: ACR Open Rheumatology, Vol 2, Iss 11, Pp 662-671 (2020)
Objective This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard‐of‐care (SOC) treatment
Externí odkaz: https://doaj.org/article/bb81072b122a4bb88073ca8840742823
Zobrazit plný text záznamu
2
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Autor: Thomas J. Schall, Pirow Bekker, Classic Investigators, Andrew S. Bomback, Brad H. Rovin, Christian Pagnoux, John L. Niles, Robert Spiera, Antonia Potarca, Peter A. Merkel, Richard A.H. Jimenez
Publikováno v: ACR Open Rheumatology, Vol 2, Iss 11, Pp 662-671 (2020)
ACR Open Rheumatology
Objective This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with g
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa9fed80daebe87ee4df42e0f5585432
https://doi.org/10.1002/acr2.11185
Zobrazit plný text záznamu
3
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy - an open-label pilot study
Autor: Annette Bruchfeld, Hasan Magin, Patrick Nachman, Samir Parikh, Richard Lafayette, Antonia Potarca, Shichang Miao, Pirow Bekker
Background Improvement of proteinuria as a marker for disease activity is associated with a better renal outcome in immunoglobulin A nephropathy (IgAN). Complement is an effector pathway in IgA-mediated kidney injury. Avacopan, a selective C5a recept
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b34dde9ad9db77f829c60c4c0f0bdc
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-183928
Zobrazit plný text záznamu
4
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Autor: Thomas J. Schall, Michel Jadoul, David Jayne, Franziska Grundmann, Patrick B. Hamilton, Matthias Schaier, Lorraine Harper, Vladimír Tesař, Annette Bruchfeld, Pirow Bekker, Mårten Segelmark, Antonia Potarca, Istvan Szombati, Michael Venning, Volker Burst
Publikováno v: Journal of the American Society of Nephrology. 28:2756-2767
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administere
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad7aabff13851a97cc627e4c2314247
https://doi.org/10.1681/asn.2016111179
Zobrazit plný text záznamu
8
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
Autor: Dick, de Zeeuw, Pirow, Bekker, Elena, Henkel, Christopher, Hasslacher, Ioanna, Gouni-Berthold, Heidrun, Mehling, Antonia, Potarca, Vladimir, Tesar, Hiddo J Lambers, Heerspink, Thomas J, Schall, A, Woodman
Publikováno v: Lancet Diabetes & Endocrinology, 3(9), 687-696. ELSEVIER SCIENCE INC
Summary Background Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Residual risk i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a20ed6401454c1bf70b854352a1f9ec1
https://research.rug.nl/en/publications/0e075502-4829-4112-963c-6d47c99c6649
Zobrazit plný text záznamu
9
Abstract B24: Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase 1B pancreatic cancer trial
Autor: Israel F. Charo, Pirow Bekker, Sabrina Cheng, Lisa Lohr, Andrea Wang-Gillam, Aram F. Hezel, Antonia Potarca, Marcus Smith Noel, Bin Zhao, Thomas J. Schall, Shichang Miao, Stefan Sleijfer, Ferry A.L.M. Eskens
Publikováno v: Molecular Cancer Therapeutics. 14:B24-B24
Introduction: The monocyte chemoattractant protein-1/ chemokine receptor 2 (CCR2) axis regulates the recruitment of inflammatory monocytes to sites of inflammation and cancer. CCR2 inhibition in preclinical models has resulted in diminished numbers o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e6ac12ed0a10f802b1c6b756e1474cd
https://doi.org/10.1158/1535-7163.targ-15-b24
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje